Merck narrowed its 2026 sales guidance and hiked its adjusted profit outlook.

Q1 earnings beat lifts shares; 2026 guidance narrows as Keytruda grows, Gardasil declines and R&D jumps on deals.

By Deena Beasley and Mariam Sunny April 30 (Reuters) - Merck on Thursday beat first-quarter sales expectations on strong ...

Merck reported higher first-quarter sales and raised its full-year earnings guidance as demand for its flagship Keytruda ...

Merck is scheduled to report first-quarter earnings on April 30, during market hours, with analysts expecting a strong ...

Merck topped first-quarter sales estimates as Winrevair and injectable Keytruda Qlex helped support revenue growth.

The drugmaker posted $16.29 billion in quarterly revenue, topping Wall Street forecasts, though a big acquisition charge ...

Merck's Q1 sales surpassed expectations, driven by strong demand for Keytruda. Despite acquisition-related losses, investors ...

On the heels of several big buys, Merck still has eyes for M&A—particularly in the oncology, immunology and cardiometabolic ...

As Merck considers its life after Keytruda, much will depend on the performance of a pair of respiratory products it gained ...

Merck & Co reported a loss in Q1 due to acquisition charges despite increased cancer and respiratory drugs sales. Revenue was $16.3 billion, beating estimates. Keytruda sales rose 12% to $8 billion, ...

Merck built a wall of patents that keeps a cancer drug's price – and its profits – high. Hospitals often add to the cost for American patients.